Moreover, this in vitro study provides significant findings for a combination treatment of silenced USP8 and docetaxel in PCa therapeutics and to overcome docetaxel-mediated chemoresistance, which may guide to proceed future animal model experiments to establish USP8 as a clinically potential therapeutic agent for PCa. This evidence concerns the gene USP8 and posterior cortical atrophy.